Multiple myeloma treatments -Abecma & Carvykti - that raised concerns among regulators because of an increased rate of “early deaths” during clinical trials managed to get a unanimous vote from the U.S. Food and Drug Administration FDA to move forward with development, citing that the benefits outweigh the risks.